Triazine anticonvulsants

Definition and Classification

Triazine anticonvulsants represent a subclass of antiepileptic drugs (AEDs) structurally characterized by a triazine ring, a six-membered heterocyclic ring containing three nitrogen atoms. This unique structure imparts anticonvulsant, mood-stabilizing, and neuroprotective effects. The prototypical and currently only clinically significant member of this class is Lamotrigine, which is chemically categorized as a phenyltriazine derivative.

Unlike broader antiepileptic drug classes that include multiple agents, the triazine anticonvulsant class is singular, with lamotrigine as its primary agent due to its distinct mechanism, structural specificity, and clinical applications.

---

Generic Name

• Lamotrigine

---

Brand Names

• Lamictal® (originator brand)

• Generic forms widely available globally under various brand names such as:

  • Lamotrigine Teva

  • Lamotrigine Sandoz

  • Lamictal XR (extended-release)

---

Chemical Structure

• Chemical class: Phenyltriazine derivative

• Molecular formula: C9H7Cl2N5

• Triazine ring system contributes to its voltage-gated sodium channel modulation, giving it antiepileptic and mood-stabilizing properties

---

Mechanism of Action

Lamotrigine acts via multiple complementary mechanisms to exert its anticonvulsant effects:

1. Voltage-gated sodium channel inhibition

   • Stabilizes presynaptic membranes

   • Inhibits repetitive firing of neurons

   • Reduces glutamate and aspartate release (excitatory neurotransmitters)

2. Calcium channel modulation

   • Inhibits high-voltage-activated N-type calcium channels

   • Decreases neurotransmitter release

3. Presynaptic glutamate release inhibition

   • Reduces excitatory synaptic transmission

4. Mood stabilization

   • Mechanism unclear but thought to involve modulation of cortical-limbic glutamatergic transmission

   • Particularly effective in bipolar depression, unlike most AEDs

---

Approved Clinical Indications

Lamotrigine is FDA-approved and internationally authorized for a variety of neurologic and psychiatric conditions:

1. Epilepsy

   • Focal (partial) seizures: Monotherapy and adjunctive therapy

   • Generalized tonic-clonic seizures: Adjunctive treatment

   • Lennox–Gastaut syndrome: Adjunctive therapy in adults and children ≥2 years

2. Bipolar I Disorder

   • Maintenance treatment of bipolar disorder

   • Particularly effective in bipolar depression prevention

   • Not useful for acute mania

---

Off-label Uses

• Neuropathic pain

• Borderline personality disorder

• Treatment-resistant unipolar depression

• PTSD

• Migraine prophylaxis (investigational)

---

Formulations Available

• Oral Tablets: 25 mg, 50 mg, 100 mg, 200 mg

• Chewable Dispersible Tablets: For pediatric or geriatric use

• Orally Disintegrating Tablets (ODTs): Lamictal ODT

• Extended-Release Tablets: Lamictal XR for once-daily dosing in epilepsy

• No parenteral (injectable) form available

---

Pharmacokinetics

• Absorption: Well absorbed orally (~98%)

• Peak Plasma: 1.5–4.8 hours (immediate-release); ~5–7 hours (XR)

• Protein Binding: 55%

• Metabolism: Primarily via glucuronidation in liver (UGT1A4 enzyme)

• Elimination Half-life:

  • 25–33 hours in monotherapy

  • ↓ to 13–15 hours with enzyme inducers (e.g., carbamazepine, phenytoin)

  • ↑ to 58–70 hours with valproate

• Excretion: Renal (mainly as glucuronide conjugate)

---

Dosing Regimens

Dosing must be individualized and titrated slowly, especially when co-administered with valproic acid, which increases lamotrigine plasma levels and risk of rash.

Monotherapy or with enzyme-inducing AEDs (without valproate):

• Start: 25 mg once daily x 2 weeks

• Increase: 50 mg once daily x 2 weeks → then increase every 1–2 weeks by 50–100 mg

• Maintenance: 200–400 mg/day in 1–2 divided doses

With valproate (enzyme inhibitor):

• Start: 25 mg every other day x 2 weeks

• Increase: 25 mg once daily x 2 weeks → then increase by 25–50 mg every 1–2 weeks

• Maintenance: 100–200 mg/day

Bipolar disorder:

• Maintenance dose: 200 mg/day

• Start: 25 mg once daily, titrate slowly over 6 weeks to target

---

Adverse Effects

Lamotrigine is generally well tolerated but can cause serious dermatological and systemic reactions:

Common:

• Headache

• Nausea, vomiting

• Dizziness

• Insomnia

• Diplopia, blurred vision

• Ataxia

• Rash (10% of users)

Serious:

• Stevens–Johnson syndrome (SJS)

• Toxic epidermal necrolysis (TEN)

• Drug reaction with eosinophilia and systemic symptoms (DRESS)

• Aseptic meningitis

• Blood dyscrasias (rare)

• Suicidal ideation (class-wide warning for antiepileptics)

Risk factors for rash:

• Rapid titration

• Co-administration with valproate

• High starting doses

• Pediatric age

---

Drug Interactions

Interacting Drug	Effect on Lamotrigine
Valproic acid	Inhibits metabolism → ↑ Lamotrigine levels (2×)
Carbamazepine	Induces UGT enzymes → ↓ Lamotrigine levels
Phenytoin	↓ Lamotrigine plasma levels
Oral contraceptives	↑ glucuronidation → ↓ Lamotrigine levels
Rifampin	Enzyme induction → ↓ Lamotrigine levels
Sertraline	May cause additive CNS effects

Contraceptive Consideration:

• Estrogen-containing oral contraceptives can reduce lamotrigine concentrations by up to 60%

• Doses may need to be adjusted if contraceptive is initiated or discontinued

---

Contraindications and Cautions

• Known hypersensitivity to lamotrigine or any component

• Caution in hepatic impairment → monitor liver function, dose reduction may be needed

• Renal impairment: Dose adjustment not usually necessary unless severe

• Pregnancy:

  • Category C (old system); now risk not ruled out

  • Preferred AED in pregnancy due to lower teratogenic risk compared to valproate

  • However, clearance increases significantly during pregnancy, so dose must be adjusted

---

Therapeutic Drug Monitoring (TDM)

• Routine TDM not standard

• May be considered:

  • In pregnancy (to guide dose adjustments)

  • Suspected non-adherence

  • Toxicity symptoms

• Therapeutic range (suggested): 3–15 mcg/mL

---

Clinical Advantages

• Broad-spectrum AED

• Effective mood stabilizer—especially for bipolar depression

• Low teratogenicity risk

• Favorable weight profile (weight-neutral)

• No sedating or cognitive dulling effects, unlike many older AEDs

• Minimal drug-drug interactions, especially when not combined with enzyme modifiers

---

Clinical Limitations

• Risk of life-threatening rash requires slow titration

• Not effective for acute mania

• Dose affected by other drugs (requires close monitoring in polytherapy)

• Formulation limitations (no IV or rapid-onset versions)

---

Comparison to Other AEDs

Feature	Lamotrigine	Valproate	Carbamazepine	Levetiracetam
Sodium channel block	Yes	Weak	Strong	No
Rash risk	Moderate–High	Moderate	High	Low
Mood stabilization	Yes (bipolar depression)	Yes (mania)	Weak	No
Teratogenicity	Low	High	Moderate	Low
Drug interactions	Few (monotherapy)	Extensive	Extensive	Few
Sedation	Low	Moderate	High	Moderate

Use in Pediatrics

• Approved for children ≥2 years (adjunctive)

• Dosing is weight-based and requires careful titration

• Rash risk is higher than in adults → slow titration essential

• Often used in epilepsy syndromes such as Lennox–Gastaut

---

Use in the Elderly

• Start at lower dose due to altered pharmacokinetics

• Favorable profile: less sedation, low orthostatic hypotension risk

• Useful in comorbid depression + seizure or neuropathy

---

Monitoring and Patient Education

• Educate about signs of rash: Stop drug immediately if rash appears

• Emphasize adherence to titration schedule

• Avoid alcohol and abrupt discontinuation (risk of seizures)

• Women of childbearing age: discuss contraceptive interactions and pregnancy planning

---

Regulatory Status

• FDA-approved for epilepsy and bipolar I disorder

• Schedule: Non-controlled substance

• Included in WHO Model List of Essential Medicines